Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis

The Australia and New Zealand Sclerosis Genetics Consortium (ANZgene), 2009, Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20, Nat. Genet., 41, 824, 10.1038/ng.396 Bannerman, 2007, Enhanced visualization of axon pathology in EAE using thy1-YFP transgenic mice, J. Neurol. Sci., 260, 23, 10.1016/j.jns.2007.03.020 Bannerman, 2007, Astrogliosis in EAE spinal cord: derivation from radial glia, and relationships to oligodendroglia, Glia, 55, 57, 10.1002/glia.20437 Bennett, 2009, Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications, Clin. Neuropharm., 32, 121, 10.1097/WNF.0b013e3181880359 Cheng, 2010, Internalization of the opioid growth factor, [Met5]-enkephalin, is dependent on clathrin-mediated endocytosis to downregulate cell proliferation, Amer. J. Physiol. Regul. Integr. Comp. Physiol., 299, R774, 10.1152/ajpregu.00318.2010 Cheng, 2007, The OGF–OGFr axis utilizes the p16 pathway to inhibit progression of human squamous cell carcinoma of the head and neck, Cancer Res., 67, 10511, 10.1158/0008-5472.CAN-07-1922 Cheng, 2009, The OGF–OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation, Mol. Biol. Cell, 20, 319, 10.1091/mbc.e08-07-0681 Cheng, 2009, Dependence on nuclear localization signals of the opioid growth factor receptor in the regulation of cell proliferation, Exp. Biol. Med., 234, 532, 10.3181/0901-RM-16 Cheng, 2010, Regulation of cell proliferation by the opioid growth factor receptor is dependent on karyopherin β and Ran for nucleocytoplasmic trafficking, Exp. Biol. Med., 235, 1093, 10.1258/ebm.2010.010139 Cree, 2010, Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis, Ann. Neurol., 68, 145 Csontos, 1979, Elevated plasma β-endorphin levels in pregnant women and their neonates, Life Sci., 25, 835, 10.1016/0024-3205(79)90541-1 Dass, 1996, Phosphorylation of enkephalins enhances their proteolytic stability, Life Sci., 58, 1039, 10.1016/0024-3205(96)00057-4 Encinas, 1996, Genetic analysis of susceptibility to experimental autoimmune encephalomyelitis in a cross between SJL/J and B10.S mice, J. Immunol., 157, 2186, 10.4049/jimmunol.157.5.2186 Ercolini, 2006, Mechanisms of immunopathology in murine models of central nervous system demyelinating disease, J. Immunol., 176, 3293, 10.4049/jimmunol.176.6.3293 Forte, 2007, Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis, Proc. Natl. Acad. Sci. USA, 104, 7558, 10.1073/pnas.0702228104 Gironi, 2000, β-endorphin concentrations in peripheral blood mononuclear cells of patients with multiple sclerosis, Arch. Neurol., 57, 1178, 10.1001/archneur.57.8.1178 Gironi, 2008, A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis, Mult. Scler., 14, 1076, 10.1177/1352458508095828 Isayama, 1991, Localization of preproenkephalin A mRNA in the neonatal rat retina, Brain Res. Bull., 27, 805, 10.1016/0361-9230(91)90212-3 Jankovic, 1991, Enkephalins and immune inflammatory reactions, Acta Neurol., 13, 433 Leslie, 1987, Methods used for the study of opioid receptors, Pharmacol. Rev., 39, 197 MacNamara, 2005, Increased epitope-specific CD8+ T cells prevent murine coronavirus spread to the spinal cord and subsequent demyelination, J. Virol., 79, 3370, 10.1128/JVI.79.6.3370-3381.2005 Milicevic, 2003, Ribavarin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats, J. Neurosci. Res., 72, 268, 10.1002/jnr.10552 Pandey, 2009, Clinically isolated syndrome and multiple sclerosis: rethinking the arsenal, Curr. Treat. Options Neurol., 11, 193, 10.1007/s11940-009-0023-7 Rizvi, 2004, Current approved options for treating patients with multiple sclerosis, Neurology, 63, S8, 10.1212/WNL.63.12_suppl_6.S8 Roy, 1994, Serum antibody for somatostatin-14 and prodynorphin 209-240 in patients with obsessive–compulsive disorder, schizophrenia, Alzheimer's disease, multiple sclerosis, and advanced HIV infection, Biol. Psychiatry, 35, 335, 10.1016/0006-3223(94)90037-X Sharafaddinzadeh, 2010, The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial, Mult. Scler., 16, 964, 10.1177/1352458510366857 Sidman, 1979 Smith, 2004, Treatment of advanced pancreatic cancer with opioid growth factor, Anticancer Drugs, 15, 203, 10.1097/00001813-200403000-00003 Smith, 2010, Opioid growth factor (OGF) improves clinical benefit and survival in patients with advanced pancreatic cancer, Open Access J. Clin. Trials, 2, 37 Smith, 2007, Low dose naltrexone therapy improves Crohn's disease, Amer. J. Gastroenterol., 102, 820, 10.1111/j.1572-0241.2007.01045.x Stichel, 2007, Inflammatory processes in the aging mouse brain, Neurobiol. Aging, 28, 1507, 10.1016/j.neurobiolaging.2006.07.022 Suen, 1997, A critical role for lymphotoxin in experimental allergic encephalomyelitis, J. Exp. Med., 186, 1233, 10.1084/jem.186.8.1233 Tsunoda, 2001, Prolonged gray matter disease without demyelination caused by Theiler's murine encephalomyelitis virus with a mutation in VP2 puff B, J. Virol., 75, 7494, 10.1128/JVI.75.16.7494-7505.2001 Van der Walt, 2010, Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade, Pharmacol. Therap., 126, 82, 10.1016/j.pharmthera.2010.01.006 Weiner, 2009, The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?, Ann. Neurol., 65, 239, 10.1002/ana.21640 Zagon, 2011, B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases, Immunobiology, 216, 173, 10.1016/j.imbio.2010.06.001 Zagon, I.S., Donahue, R.N., Bonneau, R.H., McLaughlin, P.J., 2011b. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met5]-enkephalin)-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Immunobiology (epub ahead of print, Sept. 29, 2010). Zagon, 1989, Characterization of zeta (ζ): a new opioid receptor involved in growth, Brain Res., 482, 297, 10.1016/0006-8993(89)91192-X Zagon, 1994, Preproenkephalin mRNA expression in the developing and adult rat brain, Mol. Brain Res., 21, 85, 10.1016/0169-328X(94)90381-6 Zagon, 1983, Naltrexone modulates tumor response in mice with neuroblastoma, Science, 221, 671, 10.1126/science.6867737 Zagon, 1983, Increased brain size and cellular content in infant rats treated with an opiate antagonist, Science, 221, 1179, 10.1126/science.6612331 Zagon, 1984, Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid systems in cancer, Life Sci., 35, 409, 10.1016/0024-3205(84)90651-9 Zagon, 1989, Naloxone modulates body and organ growth of rats: dependency on the duration of opioid receptor blockade and stereospecificity, Pharmacol. Biochem. Behav., 33, 325, 10.1016/0091-3057(89)90508-X Zagon, 1989, Endogenous opioids regulate growth of neural tumor cells in culture, Brain Res., 490, 14, 10.1016/0006-8993(89)90425-3 Zagon, 1991, Identification of opioid peptides regulating proliferation of neurons and glia in the developing nervous system, Brain Res., 542, 318, 10.1016/0006-8993(91)91585-O Zagon, 1995, Gene-peptide relationships in the developing rat brain: the response of preproenkephalin mRNA and [Met5]-enkephalin to acute opioid antagonist (naltrexone) exposure, Mol. Brain Res., 33, 111, 10.1016/0169-328X(95)00119-D Zagon, 2009, Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis, Exp. Biol. Med., 234, 1383, 10.3181/0906-RM-189 Zagon, 2010, Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis, Brain Res., 1310, 154, 10.1016/j.brainres.2009.11.026 Zagon, 2003, Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea, Brain Res., 967, 37, 10.1016/S0006-8993(02)04172-0 Zagon, 2005, Nucleocytoplasmic distribution of opioid growth factor (OGF) and its receptor (OGFr) in tongue epithelium, Anat. Rec., 282A, 24 Zagon, 2000, Cloning, sequencing, chromosomal location, and function of a cDNA encoding the opioid growth factor receptor (OGFr) in humans, Brain Res., 856, 75, 10.1016/S0006-8993(99)02330-6 Ziaber, 2000, Increased expression of neutral endopeptidase (NEP) and aminopeptidase N (APN) on peripheral blood mononuclear cells in patients with multiple sclerosis, Immunol. Lett., 71, 127, 10.1016/S0165-2478(99)00176-5 Ziaber, 1999, The immunoregulatory abilities of polymorphonuclear neutrophils in the course of multiple sclerosis, Mediat. Inflamm., 7, 335, 10.1080/09629359890857